Go Pro
→ The Pentagon Has 120 Days to Solve This Critical Mineral Problem (From The Tomorrow Investor) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$14.08
$13.98
$7.48
▼
$15.23
$55.33B0.561.13 million shs204,303 shs
IPSEN stock logo
IPSEY
IPSEN
$41.97
$46.20
$32.02
▼
$51.10
$14.07B0.43611 shs106 shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$39.66
+1.7%		$35.88
$18.21
▼
$40.79
$46.06B0.876.83 million shs1.68 million shs
UCB SA stock logo
UCBJY
UCB
$119.80
-0.3%		$127.81
$114.53
▼
$168.76
$45.29B0.4538,756 shs13,574 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-0.71%+0.21%-0.28%+6.99%+74.91%
IPSEN stock logo
IPSEY
IPSEN
-1.03%-9.21%-11.83%-9.74%+23.19%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-1.16%+1.27%+5.80%+16.09%+101.09%
UCB SA stock logo
UCBJY
UCB
-1.35%+1.73%-6.49%-18.17%-0.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$14.08
$13.98
$7.48
▼
$15.23
$55.33B0.561.13 million shs204,303 shs
IPSEN stock logo
IPSEY
IPSEN
$41.97
$46.20
$32.02
▼
$51.10
$14.07B0.43611 shs106 shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$39.66
+1.7%		$35.88
$18.21
▼
$40.79
$46.06B0.876.83 million shs1.68 million shs
UCB SA stock logo
UCBJY
UCB
$119.80
-0.3%		$127.81
$114.53
▼
$168.76
$45.29B0.4538,756 shs13,574 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-0.71%+0.21%-0.28%+6.99%+74.91%
IPSEN stock logo
IPSEY
IPSEN
-1.03%-9.21%-11.83%-9.74%+23.19%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-1.16%+1.27%+5.80%+16.09%+101.09%
UCB SA stock logo
UCBJY
UCB
-1.35%+1.73%-6.49%-18.17%-0.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
3.13
BuyN/AN/A
IPSEN stock logo
IPSEY
IPSEN
2.00
HoldN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.92
Moderate Buy$43.7310.26% Upside
UCB SA stock logo
UCBJY
UCB
2.50
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest IPSEY, BAYRY, TEVA, and UCBJY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$50.00
9/17/2026
IPSEN stock logo
IPSEY
IPSEN
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
9/16/2026
UCB SA stock logo
UCBJY
UCB
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/9/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$45.00
9/8/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C) ➝ Hold (C-)
9/8/2026
IPSEN stock logo
IPSEY
IPSEN
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeEqual Weight ➝ Underweight
9/4/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$42.00 ➝ $48.00
8/21/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/12/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$40.00 ➝ $42.00
8/4/2026
UCB SA stock logo
UCBJY
UCB
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/3/2026
UCB SA stock logo
UCBJY
UCB
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeModerate Sell ➝ Hold
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$51.55B1.07$2.17 per share6.50$7.50 per share1.88
IPSEN stock logo
IPSEY
IPSEN
$4.16B3.38$5.45 per share7.70$14.64 per share2.87
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$17.26B2.68$3.74 per share10.60$6.88 per share5.76
UCB SA stock logo
UCBJY
UCB
$8.76B5.17N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
-$4.10B-$0.51N/A10.512.13-3.80%16.77%4.53%11/3/2026 (Estimated)
IPSEN stock logo
IPSEY
IPSEN
$501.78MN/AN/A10.57N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.41B$0.6065.8813.184.934.08%32.64%6.34%11/4/2026 (Estimated)
UCB SA stock logo
UCBJY
UCB
$1.76BN/AN/A15.221.01N/AN/AN/AN/A

Latest IPSEY, BAYRY, TEVA, and UCBJY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2026Q2 2026
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.23$0.29+$0.06$0.07$12.31 billion$12.53 billion
7/29/2026Q2 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.08$0.02-$0.06-$0.49$4.02 billion$4.14 billion
6/30/2026Q2 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/A$0.02N/A-$0.49N/A$4.14 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
$0.020.14%N/AN/A N/A
IPSEN stock logo
IPSEY
IPSEN
$0.300.71%N/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
UCB SA stock logo
UCBJY
UCB
$0.530.44%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
1.05
1.04
0.67
IPSEN stock logo
IPSEY
IPSEN
N/A
1.96
1.79
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
1.56
0.88
0.67
UCB SA stock logo
UCBJY
UCB
0.20
1.38
1.04

Institutional Ownership

CompanyInstitutional Ownership
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/A
IPSEN stock logo
IPSEY
IPSEN
N/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%
UCB SA stock logo
UCBJY
UCB
N/A

Insider Ownership

CompanyInsider Ownership
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
N/A
IPSEN stock logo
IPSEY
IPSEN
N/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.54%
UCB SA stock logo
UCBJY
UCB
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
88,0783.93 billionN/ANot Optionable
IPSEN stock logo
IPSEY
IPSEN
5,535335.26 millionN/ANot Optionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
33,9501.17 billion1.16 billionOptionable
UCB SA stock logo
UCBJY
UCB
10,117378.04 millionN/ANot Optionable

Recent News About These Companies

UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
September 24 at 3:23 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4949132-ucb-sa-ucbjy-presents-at-j-p-morgan-ceo-call-series-transcript
UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
September 24 at 3:23 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4948988-ucb-sa-ucbjy-presents-at-bank-of-america-global-healthcare-conference-2026-transcript
UCB stock edges lower as Zacks upgrades rating and Belgian benchmark slips
September 19, 2026  |  ad-hoc-news.deA
UCB (UCBJY) Upgraded to Buy: Here's Why
September 18, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2992228/ucb-ucbjy-upgraded-to-buy-here-s-why?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_12_zacks_rank_upgrade-2992228
UCB's CIMZIA Receives FDA Breakthrough Therapy Designation In Pregnant Women With APS
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689622/ucb-s-cimzia-receives-fda-breakthrough-therapy-designation-in-pregnant-women-with-aps.aspx
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
September 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2983369/trump-s-mfn-push-goes-beyond-big-pharma-adds-9-mid-sized-drugmakers?cid=cs-stocknewsapi-ft-analyst_blog|industry_focus-2983369
UCB ADR (UCBJY) Ratios
July 3, 2026  |  uk.investing.comhttps://uk.investing.com/equities/ucb-sa-ratios
UCB SA (UCBJY) Analyst/Investor Day Transcript
June 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4914509-ucb-sa-ucbjy-analyst-investor-day-transcript
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial
May 19, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/ucb-says-bimzelx-beat-abbvie-s-skyrizi-in-psoriatic-arthritis-trial/ar-AA23zEja
UCB ADR Stock Price History
May 16, 2026  |  investing.comhttps://www.investing.com/equities/ucb-sa-historical-data
Belgian pharma UCB to buy US.-based Neurona for up to $1.15B
April 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/belgian-pharma-ucb-to-buy-us-based-neurona-for-up-to-1-15b/ar-AA219w9t
UCB (UCBJY) Upgraded to Strong Buy: Here's What You Should Know
April 15, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2900893/ucb-ucbjy-upgraded-to-strong-buy-here-s-what-you-should-know
Belgium's UCB in autoimmune drug deal with Antengene
March 3, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/belgiums-ucb-autoimmune-drug-deal-with-antengene-2026-03-04/
Berenberg maintains UCB SA - depositary receipt (UCBJY) buy recommendation
December 16, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/berenberg-maintains-ucb-sa-depositary-receipt-ucbjy-buy-recommendation/ar-AA1StuYI
Recent Price Trend in UCB (UCBJY) is Your Friend, Here's Why
September 25, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2756848/recent-price-trend-in-ucb-ucbjy-is-your-friend-here-s-why?cid=cs-stocknewsapi-ft-tale_of_the_tape|recent_price_strength_screen-2756848
UCB (UCBJY) Is a Great Choice for 'Trend' Investors, Here's Why
September 9, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2748540/ucb-ucbjy-is-a-great-choice-for-trend-investors-here-s-why?cid=cs-stocknewsapi-ft-tale_of_the_tape|recent_price_strength_screen-2748540
All You Need to Know About UCB (UCBJY) Rating Upgrade to Strong Buy
August 22, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/all-you-need-to-know-about-ucb-ucbjy-rating-upgrade-to-strong-buy/ar-AA1L2zt2
Here's Why Momentum in UCB (UCBJY) Should Keep going
August 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/heres-why-momentum-in-ucb-ucbjy-should-keep-going/ar-AA1JWP8w
UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?
July 16, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/ucb-ucbjy-upgraded-to-strong-buy-what-does-it-mean-for-the-stock/ar-AA1IArh0
UCB SA’s Growth Potential: Buy Rating on Bimzelx’s Transformative Impact
July 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/ratings/ucb-sas-growth-potential-buy-rating-on-bimzelxs-transformative-impact-ratings?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bayer Aktiengesellschaft stock logo

Bayer Aktiengesellschaft OTCMKTS:BAYRY

$14.08 0.00 (0.00%)
As of 11:24 AM Eastern

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

IPSEN stock logo

IPSEN OTCMKTS:IPSEY

$41.97 0.00 (0.00%)
As of 09/23/2026 03:42 PM Eastern

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$39.66 +0.65 (+1.67%)
As of 11:46 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

UCB stock logo

UCB OTCMKTS:UCBJY

$119.80 -0.36 (-0.30%)
As of 11:24 AM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas